DHT Hair Loss: Trichologist-Led Treatment for Androgen-Driven Hair Thinning

DHT (dihydrotestosterone) is the primary hormone responsible for androgenetic alopecia, the most common form of progressive hair loss in both men and women. DHT does not cause hair loss in everyone. The key factor is genetic sensitivity: individuals with androgen-sensitive follicles have hair follicles that express high levels of androgen receptors, making them responsive to DHT's miniaturizing effect. DHT binds to these receptors and triggers the follicle to progressively shrink, producing thinner and shorter hairs with each growth cycle. Follicles on the sides and back of the head typically lack this sensitivity, which is why those areas retain hair even in advanced pattern baldness. At Atlanta Trichology, trichoscopy identifies exactly which follicles are miniaturizing and how far the process has progressed, giving your trichologist a precise map for treatment.

DHT is a potent androgen hormone created when the enzyme 5-alpha reductase converts testosterone into dihydrotestosterone. DHT is 3 to 5 times more potent than testosterone at binding to androgen receptors. In genetically sensitive follicles, DHT binding triggers a cascade that shortens the growth phase of the hair cycle, reduces blood supply to the dermal papilla (the follicle's growth center), and causes the follicle to physically shrink over successive cycles. This process is called follicular miniaturization. The hair shaft produced by each cycle becomes thinner, shorter, and lighter in color. Eventually, the follicle produces only a tiny, nearly invisible vellus hair, or stops producing visible hair entirely. The follicle itself is still alive. Treatment that stimulates the follicle and reduces DHT pressure can reverse early-stage miniaturization.

Yes. DHT-driven hair loss (androgenetic alopecia) affects an estimated 40% of women by age 50. In women, the pattern typically differs from men: rather than frontal recession and crown balding, women usually experience diffuse thinning across the top of the scalp with a widening part line (the Ludwig pattern). Women produce DHT from both ovarian and adrenal androgen sources. The most common drivers of elevated DHT in women are insulin resistance, polycystic ovary syndrome (PCOS), adrenal androgen overproduction, and low sex hormone-binding globulin (SHBG). At Atlanta Trichology, Dr. Nina Ross evaluates all of these pathways. Many women with DHT-driven hair loss have never had their DHT, insulin, or SHBG tested directly, despite years of thinning.

Several evidence-based approaches reduce DHT levels or block its effects without pharmaceutical intervention. Correcting insulin resistance through dietary changes and exercise reduces androgen overproduction at the source (insulin directly stimulates ovarian and adrenal androgen synthesis). Saw palmetto has demonstrated mild 5-alpha reductase inhibition in clinical studies, though its effect is significantly weaker than pharmaceutical blockers. Pumpkin seed oil, green tea extract, and zinc have shown DHT-modulating properties in limited research. At Atlanta Trichology, Dr. Nina Ross evaluates which upstream factor is driving your DHT levels (insulin resistance, adrenal dysfunction, low SHBG) and targets correction at that level rather than relying on individual supplements. Addressing the cause produces more durable results than blocking the symptom.

Signs of elevated DHT vary by gender. In women, high DHT may present as progressive hair thinning at the part line and crown, acne (particularly along the jawline and chin), excess facial or body hair (hirsutism), oily skin, and irregular menstrual cycles. In men, signs include progressive frontal recession and crown thinning, acne, and prostate changes. Many people with DHT-driven hair loss have no other symptoms. Their DHT levels may be within the 'normal' laboratory range, but their follicles are genetically sensitive to even normal amounts. This is why trichoscopy is more diagnostic than bloodwork alone for DHT hair loss. At Atlanta Trichology, the combination of trichoscopy (identifying miniaturization at the follicle) and bloodwork (measuring the hormonal environment) provides the complete picture.

DHT hair loss is progressive if left untreated, but it is not necessarily permanent. Follicles that have miniaturized (producing thinner hairs) can be stimulated to produce thicker hairs again with appropriate treatment. The degree of reversibility depends on how long the miniaturization has been occurring and whether perifollicular fibrosis (scarring around the follicle) has developed. Early-stage miniaturization (detected on trichoscopy before it is visible in the mirror) has the highest reversal potential. Advanced miniaturization where follicles have been producing only vellus hairs for many years is harder to reverse. This is why early trichoscopy screening is the most impactful step you can take. At Atlanta Trichology, the $99 evaluation identifies your miniaturization stage and gives you an honest assessment of recovery potential.

Pharmaceutical DHT blockers (finasteride, dutasteride) are clinically proven to reduce scalp DHT levels and slow or stop androgenetic alopecia progression. Finasteride reduces DHT by approximately 70%. However, pharmaceutical DHT blockers carry side effect profiles (sexual dysfunction, mood changes, hormonal disruption) that concern many patients, particularly women of childbearing age. OTC DHT-blocking shampoos and supplements provide significantly less DHT reduction and limited clinical evidence of meaningful hair density improvement when used alone. At Atlanta Trichology, the protocol provides active follicle stimulation (laser therapy, PRP, microneedling) combined with functional medicine to reduce DHT production at the hormonal source. This approach works independently of pharmaceutical DHT blockers, though it can complement them for patients who choose to take medication.

Insulin resistance is one of the most common and most frequently overlooked drivers of excess DHT in women. When cells become resistant to insulin, the body compensates by producing more insulin (hyperinsulinemia). Elevated insulin directly stimulates the ovaries and adrenal glands to produce more androgens (testosterone and DHEA-S), which are then converted to DHT by 5-alpha reductase. Elevated insulin also reduces SHBG (sex hormone-binding globulin), the protein that binds testosterone and keeps it inactive. Less SHBG means more free testosterone available for conversion to DHT. This insulin-androgen-DHT pathway is the mechanism behind hair loss in PCOS and in women with metabolic syndrome. At Atlanta Trichology, Dr. Nina Ross tests fasting insulin, glucose, and SHBG as part of every DHT hair loss evaluation. Correcting insulin resistance through targeted intervention reduces androgen production and DHT levels at the source.